Mersana Therapeutics, Inc. (MRSN)
Jan 6, 2026 - MRSN was delisted (reason: acquired by DAWN)
29.08
+0.04 (0.14%)
Inactive · Last trade price
on Jan 5, 2026
Mersana Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 33.18 | 40.5 | 36.86 | 26.58 | 0.04 | 0.83 | Upgrade
|
| Revenue Growth (YoY) | -4.76% | 9.88% | 38.65% | 61716.28% | -94.81% | -98.03% | Upgrade
|
| Cost of Revenue | 69.03 | 73.02 | 148.27 | 173.39 | 132.01 | 67.04 | Upgrade
|
| Gross Profit | -35.85 | -32.52 | -111.41 | -146.8 | -131.97 | -66.21 | Upgrade
|
| Selling, General & Admin | 31.53 | 40.81 | 59.54 | 56.96 | 36.89 | 21.9 | Upgrade
|
| Operating Expenses | 31.53 | 40.81 | 59.54 | 56.96 | 36.89 | 21.9 | Upgrade
|
| Operating Income | -67.38 | -73.34 | -170.96 | -203.77 | -168.86 | -88.11 | Upgrade
|
| Interest Expense | -2.75 | -3.87 | -4.07 | -3.33 | -1.27 | -0.36 | Upgrade
|
| Interest & Investment Income | 4.17 | 8.44 | 12.07 | 2.88 | 0.07 | 0.42 | Upgrade
|
| EBT Excluding Unusual Items | -65.95 | -68.77 | -162.96 | -204.21 | -170.06 | -88.05 | Upgrade
|
| Merger & Restructuring Charges | -4.13 | - | -8.71 | - | - | - | Upgrade
|
| Pretax Income | -70.08 | -68.77 | -171.67 | -204.21 | -170.06 | -88.05 | Upgrade
|
| Income Tax Expense | - | 0.42 | - | - | - | - | Upgrade
|
| Net Income | -70.08 | -69.19 | -171.67 | -204.21 | -170.06 | -88.05 | Upgrade
|
| Net Income to Common | -70.08 | -69.19 | -171.67 | -204.21 | -170.06 | -88.05 | Upgrade
|
| Shares Outstanding (Basic) | 5 | 5 | 5 | 4 | 3 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 5 | 5 | 4 | 3 | 2 | Upgrade
|
| Shares Change (YoY) | 2.10% | 5.54% | 23.98% | 32.69% | 14.79% | 41.37% | Upgrade
|
| EPS (Basic) | -14.09 | -14.12 | -36.96 | -54.51 | -60.24 | -35.80 | Upgrade
|
| EPS (Diluted) | -14.09 | -14.12 | -36.96 | -54.51 | -60.24 | -35.80 | Upgrade
|
| Free Cash Flow | -74.37 | -82.47 | -171.05 | -51.56 | -140.64 | -75.17 | Upgrade
|
| Free Cash Flow Per Share | -14.95 | -16.83 | -36.83 | -13.76 | -49.81 | -30.56 | Upgrade
|
| Gross Margin | -108.04% | -80.31% | - | - | - | - | Upgrade
|
| Operating Margin | -203.06% | -181.09% | -463.86% | -766.59% | -392693.02% | -10641.30% | Upgrade
|
| Profit Margin | -211.22% | -170.86% | -465.80% | -768.26% | -395488.37% | -10633.45% | Upgrade
|
| Free Cash Flow Margin | -224.14% | -203.65% | -464.12% | -193.97% | -327060.47% | -9078.38% | Upgrade
|
| EBITDA | -66.29 | -71.71 | -169.44 | -202.84 | -168 | -87.1 | Upgrade
|
| EBITDA Margin | -199.79% | -177.07% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 1.09 | 1.63 | 1.52 | 0.93 | 0.86 | 1.01 | Upgrade
|
| EBIT | -67.38 | -73.34 | -170.96 | -203.77 | -168.86 | -88.11 | Upgrade
|
| EBIT Margin | -203.06% | -181.09% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.